About this live event
The current weight loss medication landscape is rapidly reshaping weight-centric medical care - but their impact on eating disorder risk, presentation, and treatment is often overlooked. This continuing education talk explores the complex and under-recognized intersection between GLP-1 receptor agonist-containing medications (e.g., semaglutide, dulaglutide, and tirzepatide) and eating disorders across the diagnostic spectrum. Clinicians will examine how appetite suppression, weight loss reinforcement, and cultural weight bias may exacerbate disordered eating, mask symptoms, or delay diagnosis - particularly in patients with subclinical or atypical presentations. Of particular concern is the potential for GLP-1 receptor agonist-containing medications to induce or exacerbate malnutrition, complicating the clinical picture. The session will challenge common assumptions about “appropriate” candidates for GLP-1 receptor agonist-containing medications, highlight ethical and clinical blind spots, and offer practical guidance for screening, assessment, and interdisciplinary decision-making to support patient safety and recovery-oriented care.
